Transplant drug: Daclizumab (trade name zenapax) is a therapeutic humanized monoclonal antibody to the Alpha subunit of the il-2 receptor of t cells. It is used to prevent rejection in organ transplantation, especially in kidney transplants. Daclizumab is currently in phase ii clinical trials in the U.S.
Answered 6/25/2014
5.7k views
90,000 U.S. doctors in 147 specialties are here to answer your questions or offer you advice, prescriptions, and more.
Ask your question